- Language: Chinese
- 42 Pages
- Published: January 2014
- Region: China
Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2014
- Published: January 2014
- Region: China
- 42 Pages
- Huidian Research
With the mushroom growth of world diagnostic imaging equipments and apparatuses, as for X-CT contrast media, iodinated contrast media serving as the main one is witnessing unprecedented development. Iohexol is featured with great security, high contrast ratio, lower osmotic pressure and small toxicity for human bodies etc. has become the best-selling contrast media in international market. The sales amount of all kinds of contrast media across the world has exceeded USD 23 billion in 2013, with growth continued to rise at the rate of 6% to 8%.
In recent two years, as for the drug procurement in 22 cities in China, there were six major varieties of contrast media, namely, iohexol, iopromide, gadopentetate dimeglumine, iopamidol, ioversol and meglumine diatrizoate, of which the former three varieties were listed among the best-selling 200 drugs. Recently, hospitals attached more importance to instrument testing, boosting the development of contrast media market.
According to the procurement of contrast media from sampled hospitals in 16 cities, iohexol and iopromide rank first and second respectively, accounting for 43% and 32% of market shares of CT contrast media respectively in domestic market. As for domestic MRI contrast media, gadopentetate dimeglumine still plays the leading role, accounting for 83% of market shares of MRI contrast media.
At present, Bayer Health Care, GE, Shanghai Bracco Sine Pharmaceutical Corp. Ltd., Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine Co., Ltd. and BEILU Pharmaceutical Co., Ltd. dominate domestic contrast media market, they account for over 80% of market shares totally.
In recent two years, domestic hospitals with certain strength put their attention on testing and examining, so they increased investment in imaging equipments, resulting in bringing momentum for the growth of contrast media market. Competition in contrast media market is not too fierce, and overall the market is on the rising trend. With continuous input and perfection of inspection equipments in China's large-scale hospitals, contrast media market will continue go up. In addition, contrast media price is high in terms of retail sales with considerable profits, representing one of motivators for its rapid growth. It is predicted that in the next five years, with people's rising health awareness and increase of medical facilities, domestic contrast media market will maintain stable growth, with annual growth rate registering 20%.
Please allow 2 business days for translation SHOW LESS READ MORE >
1. Development Overview of Contrast Media Industry
1.1 Overview of Industry
1.1.2 Product Classification
1.2 Industry China
2. Development Overview of Global Contrast Media Industry
2.1 Development Status
2.2 Application for International Contrast Media Patents
3. Environment Analysis of China's Contrast Media Industry
3.1 China's Economic Development Environment
3.2 Policy Environment
3.2.1 National Basic Medical Insurance, Employment Injury Insurance and Maternity Insurance Drug Catalogue
3.2.2 Suggestions on Consolidating Essential Medicine System and New Operation Mechanism of Grass Roots
3.3 Domestic Technological Level of Contrast Media
3.3.1 Technical Status
3.3.2 Patent Application in China
4. Analysis on China's Contrast Media Industry
4.1 Domestic Market Status and Forecast
4.2 Segment Products
4.2.1 Much Attention on Iodized Salt Type of Products
4.2.2 Ultravist Dominates Iopromide Market
4.2.3 Imported and Domestic Iohexol Have Equal Shares
4.2.4 Iopamidol vs. Ioversol
4.2.5 Differences between Domestic and Overseas Gadopentetate Dimeglumine
4.3 Factors Affecting Contrast Media Development
4.3.1 Improvement of Social Economy
4.3.2 Wide Application of Imaging Diagnostic and Treatment Equipment
4.3.3 Improvement of Imaging Diagnostic and Treatment Method
4.3.4 Changes of Seeing a Doctor
5. Competitive Landscape of China's Contrast Media Industry
5.1 Competitiveness Analysis
5.1.1 Upstream Bargaining Power
5.1.2 Periodic Fluctuation of Consumers' Bargaining Power
5.1.3 Potential Entrant
5.1.4 Competition in the Industry
5.2 Concentration Ratio of Contrast Media Industry
5.2.1 Concentration Ratio of China's CT Contrast Media Market
5.2.2 Concentration Ratio of China's MRI (Magnetic Resonance Imaging) Contrast Media Market
6. Import and Export Data of Contrast Media Products
6.1 Import and Export Data of X-Ray Contrast Media and Diagnostic Reagent, 2010-2013
6.2 Import Sources and Export Destinations of X-Ray Contrast Media and Diagnostic Reagent, 2013
7. Domestic Major Contrast Media Manufacturing Enterprises
7.1 Yangtze River Pharmaceutical Group
7.1.1 Company Profile
7.1.2 Main Business
7.1.3 Competitive Edge
7.1.4 Business Performance
7.1.5 Future Development Strategy
7.2 BEILU Pharmaceutical Co., Ltd.
7.2.1 Company Profile
7.2.2 Main Business
7.2.3 Competitive Edge
7.2.4 Business Performance
7.2.5 Future Development Strategy
7.3 Jiangsu Hengrui Medicine Co., Ltd.
7.3.1 Company Profile
7.3.2 Main Business
7.3.3 Competitive Edge
7.3.4 Business Performance
7.3.5 Future Development Strategy
7.4 China Resources Double-crane Pharmaceutical Co., Ltd.
7.4.1 Company Profile
7.4.2 Main Business
7.4.3 Competitive Edge
7.4.4 Business Performance
7.4.5 Market Structure of Cardiac Ultrasound Contrast Media
7.5 Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
7.5.1 Company Profile
7.5.2 Main Business
7.5.3 Product Performance
8. Investment and Development Trend of Contrast Media Industry
8.1 Investment Opportunities
8.1.1 Rising Health Consciousness
8.1.2 Increasing Number of Medical Treatment Equipment (MRI Equipment)
8.2 Investment Risks
8.3 Development Trend of China's Contrast Media Industry
8.3.1 X-Ray CT Contrast Media
8.3.2 MRI Contrast Media
8.3.3 Ultrasound Contrast Media
8.4.1 Large-Scale and Specialized Enterprise Development
8.4.2 Strengthen Technology R&D
8.4.3 Scientific Enterprise Management
8.4.4 Build Brand Awareness
- Yangtze River Pharmaceutical Group
- BEILU Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.
- China Resources Double-crane Pharmaceutical Co., Ltd.
- Shanghai Xudong Haipu Pharmaceutical Co., Ltd.